Madrigal Pharmaceuticals, Inc. MDGL
420.32 USD -4.89 (-1.15%)
Nov 13, 2026, 12:20 PM EST
414.16 Day range 424.92
353.54 52-week range 615.00
- YTD
- -27.82%
- 1 year
- -18.37%
Benzinga news
benzinga.com Madrigal Pharmaceuticals Announces Data From Its Rezdiffra Trials Demonstrated 55% Participants Achieved Over 25% Improvement In Liver Stiffness, 48% Patients Reports Over 30% Improvement At 12 Months Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q4 Healthcare stocks Alnylam, Madrigal and Corcept appear oversold, with RSI near or below 30, offering potential opportunities for investors.
benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $612 to $633.
benzinga.com Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743 Truist Securities analyst Srikripa Devarakonda reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $709 to $743.
benzinga.com Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $760 Citigroup analyst Eric Joseph maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $725 to $760.
benzinga.com Madrigal Pharmaceuticals Q3 2026 Earnings Call Transcript Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Madrigal Pharmaceuticals Q3 EPS $1.83 Beats $(0.94) Estimate, Sales $431.268M Beat $404.264M Estimate Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $(0.94) by 294.68 percent. This is a 136.02 percent increase over…
benzinga.com Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the…
benzinga.com Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.- benzinga.com Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725 Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.
benzinga.com This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
benzinga.com This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinions and price targets for these stocks.- benzinga.com Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target Wolfe Research analyst Andy Chen upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Peer Perform to Outperform and announces $605 price target.
benzinga.com Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962 Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.
benzinga.com Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses…- benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $578 to $587.
benzinga.com 4 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685 Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $685.
- benzinga.com Madrigal Pharmaceuticals Receives Three Resmetirom Patents From U.S. Patent And Trademark Office New U.S. Rezdiffra patents in F2/F3 to be listed in FDA’s Orange BookU.S. Patent No. 12,667,575, directed to administering a weight-threshold step-down 60mg or 80mg resmetirom dose for patients with…
- benzinga.com B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542 B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.
- benzinga.com Madrigal Pharma Announces New Analyses Of Phase 3 Data And Real-World Evidence Demonstrating Rezdiffra Reduced Markers Of Cardiovascular And Liver-Related Risk In Patients With MASH Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASHRezdiffra improved atherogenic lipid profiles…
- benzinga.com Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709 Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $640 to $709.
- benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $587 to $578.
- benzinga.com Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $649 Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and lowers the price target from $652 to $649.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call - benzinga.com HC Wainwright & Co. Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target HC Wainwright & Co. analyst Andrew S. Fein reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and maintains $620 price target.
- benzinga.com Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over…
- benzinga.com Arrowhead Announces Exclusive Worldwide License Agreement With Madrigal For ARO-PNPLA3, Clinical Stage RNAi Therapeutic To Reduce Liver Expression Of PNPLA3 As Potential Treatment For Metabolic Dysfunction-Associated Steatohepatitis - Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH- Phase 1 data published in The New England Journal of…
- benzinga.com Madrigal Pharmaceuticals Announces Exclusive Global License Agreement With Arrowhead Pharmaceuticals For ARO-PNPLA3 Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene,…
benzinga.com Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - benzinga.com Earnings Scheduled For February 19, 2026
benzinga.com Earnings Preview For Madrigal Pharmaceuticals 
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com Madrigal Pharmaceuticals inks an exclusive global license agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical MASH programs For An Upfront $60M And Milestone Payment Of $4.4B Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an…
- benzinga.com Barclays Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $964 Barclays analyst Eliana Merle initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $964.
benzinga.com 10 Analysts Have This To Say About Madrigal Pharmaceuticals - benzinga.com Citizens Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $745 Citizens analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the price target from $527 to $745.
benzinga.com Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? A wave of analyst downgrades, outlook resets and company-specific headlines pushed last week's biggest large-cap losers lower, led by First Solar, Roblox, and Madrigal.- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
- benzinga.com Madrigal Pharmaceuticals Strikes License Agreement With Pfizer For Ervogastat Inhibitor Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an…
- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
- benzinga.com Piper Sandler Maintains Overweight on Madrigal Pharmaceuticals, Raises Price Target to $900 Piper Sandler analyst Yasmeen Rahimi maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and raises the price target from $540 to $900.
- benzinga.com B. Riley Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $670 B. Riley Securities analyst William Woods maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $560 to $670.
- benzinga.com HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $620 HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $568 to $620.
benzinga.com Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - benzinga.com Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $650 Oppenheimer analyst Jay Olson maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and raises the price target from $600 to $650.
- benzinga.com Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $640 Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $580 to $640.
- benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $526 to $587.
- benzinga.com HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $568 HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $500 to $568.